Should we treat the somatopause?

Journal of Endocrinological Investigation

Volumn 22, Issue 10 SUPPL. 1, 1999, Pages 4-6

  Hoffman, A R ^a,c   Ceda, G P ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PARMA   (Italy)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Aging; GH therapy; Somatopause

Indexed keywords

HUMAN GROWTH HORMONE; SOMATOMEDIN;

AGED; AGING; HORMONE SUBSTITUTION; HUMAN; METABOLISM; OBESITY; REVIEW; SPORT;

AGED; AGING; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; OBESITY; SOMATOMEDINS; SPORTS;

EID: 0033251044     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. de Boere H., Blok G.J., Voerman H.J., Phillips M., Schouten J.A. Serum lipid levels in growth hormone-deficient men. Metabolism 1994, 43: 199-203.
2. Johansson J.O., Landin K., Tengborn L., Rosen T., Bengtsson B.A. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler. Thromb. 1994, 14: 434-437.
3. Rosen T., Bengtsson B.-A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336: 285-288.
4. Ceda G.P., Dall'Aglio E., Magnacavallo A., Vargas N., Fontana V., Maggio M., Valenti G., Lee P.D.K., Hintz R.L., Hoffman A.R. The insulin-like growth factor axis and plasma lipid levels in the elderly. J. Clin. Endocrinol. Metab. 1998, 83: 499-502.
5. Borson-Chazot F., Serusclat A., Kalfallah Y., Ducottet X., Sassolas G., Bernard S., Labrousse F., Pastene J., Sassolas A., Roux Y., Berthezène F. Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. J. Clin. Endocrinol. Metab. 1999, 84: 1329-1333.
6. Sacca L., Cittadini A., Fazio S. Growth hormone and the heart. Endocr. Rev. 1994, 15: 555-573.
7. Rudman D., Feller A.G., Nagraj H.S., et al. Effects of human GH in men over 60 years old. N. Engl. J. Med. 1990, 323: 1-6.
8. Marcus R., Hoffman A.R. Growth hormone as therapy for older men and women. Ann. Rev. Pharmacol. Toxicol. 1998, 38: 45-61.
9. Fryberg D.A., Gelfand R.A., Barrett E.J. Growth hormone acutely stimulated forearm muscle protein synthesis in normal humans. Am. J. Physiol. 1991, 260: 499.
10. Vandenburgh H.H., Karlisch P., Shewsky J., Feldstein R. Insulin and IGF-1 induce pronounced hypertrophy of skeletal muscle myofibers in tissue culture. Am. J. Physiol. 1991, 260: 475-484.
11. Pyka G., Wiswell R.A., Marcus R. Age-dependent effect of resistance exercise on growth hormone secretion in people. J. Clin. Endocrinol. Metab. 1992, 75: 404-407.
12. Kiel D.P., Puhl J., Rosen C.J., Berg K., Murphy J.B., MacLean D.B. Lack of an association between insulin-like growth factor-I and body composition, muscle strength, physical performance or self-reported mobility among older persons with functional limitations. J. Am. Geriatr. Soc. 1998, 46: 822-828.
13. Taaffe D.R., Pruit L., Reim J., Hintz R.L., Butterfield G., Hoffman A.R., Marcus R. Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J. Clin. Endocrinol. Metab. 1994, 79: 1361-1366.
14. Thompson J.L., Butterfield G.E., Marcus R., Hintz R.L., Van Loan M., Ghiron L., Hoffman A.R. The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. J. Clin. Endocrinol. Metab. 1995, 80: 1845-1852.
15. Thompson J.L., Butterfield G.E., Gylfadottir U.K., Yesavage J., Marcus R., Hintz R.L., Pearman A., Hoffman A.R. Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. J. Clin. Endocrinol. Metab. 1998, 83: 1477-1484.
16. Osterziel K.J., Strohm O., Schuler J., Friedrich M., Hanlein D., Willenbrock R., Anker S.D., Poole-Wilson P.A., Ranke M.B., Dietz R. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998, 351: 1233-1237.
17. Cohen P. Serum insulin-like growth factor-I levels and prostate cancer risk - interpreting the evidence. J. Natl. Cancer Inst. 1998, 90: 876-879.
18. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H., Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279: 563-566.
19. Hankinson S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., Rosner B., Speizer F.E., Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351: 1393-1396.
20. Colao A., Marzullo P., Spiezia S., Ferone D., Giaccio A., Cerbone G., Pivonello R., Di Somma C., Lombardi G. Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. J. Clin. Endocrinol. Metab. 1999, 84: 1986-1991.